Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announced this morning that yesterday the Directors below purchased ordinary shares of 25 pence in the Company.
Director No of Ordinary Price Resultant % of the
Shares paid shareholding issued
purchased share
capital
-------------------------------- --------------- ------- -------------- ---------
Dr Michael Sinclair,
Executive Chairman 100,000 28.35p 4,728,229 6.51%
-------------------------------- --------------- ------- -------------- ---------
Dr Enrico Vanni, Non-Executive
Director 100,000 28.50p 923,946 1.27%
